Elafibranor
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Elafibranor: From Investigational Use to Predicted Amenorrhea
One-Sentence Summary
Elafibranor is not yet marketed in this jurisdiction, and no formally documented original indication or mechanism of action is currently on file. The TxGNN model predicts a possible association with Amenorrhea, with 0 clinical trials and 0 publications currently supporting this direction — this prediction rests entirely on model output.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication is on file for this drug |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Elafibranor in this evidence pack. Based on publicly known information (not part of the verified input data), Elafibranor is a PPAR-α/δ dual agonist that has been in clinical development for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) — both of which relate to lipid metabolism and bile acid homeostasis.
No mechanistic or clinical pathway currently connects PPAR-α/δ agonism to amenorrhea, which is a condition with heterogeneous causes (hypothalamic, ovarian, uterine, or drug-induced). The TxGNN score of 99.86% reflects graph-based node proximity/co-occurrence patterns in the model, not validated pharmacological or clinical evidence — a very high score in this context should not be interpreted as mechanistic support.
Given the absence of any supporting trials, literature, or plausible biological rationale, this prediction should currently be treated as hypothesis-generating only, not as an actionable repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
No marketing authorizations are currently on file for this drug (0 licenses registered; market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- This is a model-only prediction (L5) with no supporting clinical trials, literature, or mechanistic rationale; the drug is also not yet marketed and lacks a documented original indication or MOA, so it cannot proceed to safety screening (S1) at this time.
To proceed, the following is needed:
- TFDA label extraction (warnings/contraindications) — currently blocking for safety review (DG001)
- Confirmed mechanism of action via DrugBank query (DG002)
- Literature/clinical trial search specifically for Elafibranor–amenorrhea or PPAR agonist–reproductive endocrine pathway association
- Re-evaluation once mechanistic plausibility or any real-world/clinical evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.